Predicting idiosyncratic reactions remains a significant challenge due to their rarity and complexity. Genetic screening can sometimes identify individuals at risk, but it is not always practical or feasible. Current research in pharmacogenomics aims to develop more precise predictive models by understanding the genetic variations that contribute to these reactions.
